Download PDF
Thorac Cardiovasc Surg 2019; 67(08): 692-696
DOI: 10.1055/s-0038-1667325
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Thoracoscopic Resection of Fluorodeoxyglucose-Avid Mediastinal Lymph Nodes Associated with Advanced Ovarian Carcinoma

Masatsugu Hamaji
1   Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
,
Ken Yamaguchi
2   Department of Obstetrics and Gynecology, Kyoto University Hospital, Kyoto, Japan
,
Sho Koyasu
3   Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, Kyoto, Japan
,
Hiroshi Date
1   Department of Thoracic Surgery, Kyoto University Hospital, Kyoto, Japan
› Author Affiliations
Further Information

Publication History

28 April 2018

19 June 2018

Publication Date:
07 August 2018 (online)

    Permissions and Reprints All articles of this category

Abstract

The indication for surgery is controversial in patients with advanced ovarian cancer and fluorodeoxyglucose (FDG)-avid mediastinal lymph nodes. Herein we report our experience in thoracoscopic resection of FDG-avid mediastinal lymph nodes associated with advanced ovarian cancer in six patients. No perioperative or long-term mortality was noted. FDG-avid mediastinal lymph nodes in advanced ovarian carcinoma may merit thoracoscopic resection with histological confirmation for more precise staging.

Keywords

ovarian carcinoma - mediastinal lymph nodes - thoracoscopy/VATS
 

  • References

  • 1 Hynninen J, Kemppainen J, Lavonius M. , et al. A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer. Gynecol Oncol 2013; 131 (02) 389-394
    CrossrefPubMedGoogle Scholar
  • 2 Bats AS, Hugonnet F, Huchon C. , et al. Prognostic significance of mediastinal 18F-FDG uptake in PET/CT in advanced ovarian cancer. Eur J Nucl Med Mol Imaging 2012; 39 (03) 474-480
    CrossrefPubMedGoogle Scholar
  • 3 Hynninen J, Auranen A, Carpén O. , et al. FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread. Gynecol Oncol 2012; 126 (01) 64-68
    CrossrefPubMedGoogle Scholar
  • 4 Winter III WE, Maxwell GL, Tian C. , et al; Gynecologic Oncology Group Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008; 26 (01) 83-89
    CrossrefPubMedGoogle Scholar
  • 5 Tian WJ, Chi DS, Sehouli J. , et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol 2012; 19 (02) 597-604
    PubMedGoogle Scholar
  • 6 Forstner R, Sala E, Kinkel K, Spencer JA. ; European Society of Urogenital Radiology. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 2010; 20 (12) 2773-2780
    CrossrefPubMedGoogle Scholar
  • 7 Perri T, Ben-Baruch G, Kalfon S. , et al. Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: is there a case for thoracic cytoreduction?. Gynecol Oncol 2013; 131 (01) 27-31
    CrossrefPubMedGoogle Scholar
  • 8 Signorelli M, Guerra L, Pirovano C. , et al. Detection of nodal metastases by 18F-FDG PET/CT in apparent early stage ovarian cancer: a prospective study. Gynecol Oncol 2013; 131 (02) 395-399
    CrossrefPubMedGoogle Scholar